医院感染治疗市场－全球产业规模、份额、趋势、机会、预测：按药物类型、应用、地区和竞争格局划分，2021-2031年

全球医院感染治疗市场预计将从 2025 年的 96.5 亿美元成长到 2031 年的 136.5 亿美元，复合年增长率为 5.95%。

此领域涵盖用于控制患者住院期间发生的医院感染的药物製剂，例如抗生素、抗真菌药物和抗病毒药物。市场扩张的主要驱动因素是多重抗药性病原体的传播以及全球人口老化趋势。因此，需要长期住院和复杂侵入性手术的病例数量增加。此外，临床上对败血症和导管相关併发症的认识不断提高，促使医疗机构实施先进的抗菌通讯协定，从而确保了对有效治疗性介入的持续需求。

另一方面，市场成长的一大障碍是新药研发缺乏经济可行性。这导致新疗法严重短缺。除了庞大的研发成本外，短期疗法的低投资报酬率也阻碍了永续的商业性合作。根据国际药品製造商协会联合会（IFPMA）2024年的数据，只有一种抗生素候选药物处于针对四种高优先级细菌病原体的III期临床试验阶段。后期候选药物的匮乏凸显了目前阻碍产业创新的巨大资金障碍。

市场驱动因素

多重抗药性病原体的传播是推动全球医院感染治疗市场发展的主要动力。随着细菌发展出复杂的抗药性机制，标准抗生素治疗的疗效持续下降，因此亟需引进先进的最后防线疗法。医院感染，尤其是加护病房（ICU）感染的日益增多，进一步加剧了这一需求，因为ICU中的脆弱患者面临更高的感染风险。 2024年5月，世界卫生组织（WHO）在其「2024年细菌病原体优先清单」中，将15种抗药性细菌列为新药研发的首要目标。此外，2024 年 7 月，美国疾病管制与预防中心 (CDC) 在其「2021-2022 年美国抗菌素抗药性威胁」分析中报告称，COVID-19 大流行期间医院获得性抗菌素抗药性感染疾病比大流行前水准增加了 20%，这凸显了继续采取有效医疗干预措施的必要性。

同时，支持性的法规结构和政府资金在维持市场发展势头方面发挥着至关重要的作用，它们能够降低抗菌药物研发过程中面临的高风险。由于短效抗生素的商业性回报往往不足以吸引私人资本，公共部门的投资对于维持强大的临床研发管线至关重要。各国政府和国际组织正越来越多地利用激励奖励来支持生技公司进行成本高昂的早期研发工作。例如，2024年5月，英国卫生和社会保障部拨款8,500万英镑，作为「2024-2029年抗菌素抗药性国家行动计画」的一部分，用于支持国际合作和倡议倡议，以对抗抗菌素抗药性。这笔未稀释的资金将降低製药公司在研发过程中的风险，并确保有稳定的新疗法候选药物进入市场，用于应对危机。

市场挑战

全球医院感染治疗市场面临的最大障碍是新型抗菌药物研发缺乏经济可行性。这种结构性市场失灵源自于研发投入庞大，却无法产生足够的效益来弥补高成本。主要原因是，新型抗生素通常作为防止抗药性产生的最后手段，而非大规模上市。这种不利的经济环境阻碍了製药公司维持其抗菌药物产品组合，导致资本剥离和研发管线停滞。因此，难以生产市场强劲成长所需的高附加价值产品。

这些创新治疗方法的供应中断迫使市场依赖价格较低的学名药，而非昂贵的新疗法，直接限制了市场扩张。国际药品製造商协会联合会（IFPMA）2024年报告指出，这些与奖励相关的挑战导致2017年至2023年间仅有10种新抗生素获得监管机构的核准，其中只有两种被认定为创新疗法。新疗法的产量如此之低，严重限制了商机，并阻碍了市场满足不断变化的医疗需求的能力。

市场趋势

人工智慧驱动的药物发现正在从根本上重塑全球医院感染治疗市场，它加速了新型抗菌化合物的发现，而这些化合物往往被传统筛检方法所忽略。这项技术使製药公司能够快速分析庞大的化合物库，并预测其对抗药性菌株的分子水平疗效，从而重振停滞的临床试验项目。透过利用机器学习演算法，研发人员可以以前所未有的速度优化兼具安全性和有效性的先导化合物，直接解决医院感染有效治疗方法严重短缺的问题。硅谷评论（The Silicon Review）在2025年3月发表了报导，强调了这一趋势。文章指出，辉瑞正在投资20亿美元开发一个由人工智慧驱动的药物发现平台，旨在自动识别针对多重抗药性病原体的下一代治疗方法。

同时，噬菌体疗法正迅速崛起，成为传统抗生素的极具前景的替代方案。由于细菌抗药性机制导致标准药物疗效不佳，治疗重点正转向噬菌体（一种特异性靶向併中和致病菌，同时不损害有益微生物群或诱导广谱抗药性的病毒）。这一趋势标誌着模式转移生物干预，为菌血症和导管相关感染疾病等难治性疾病提供了精准的治疗选择。根据Armata Pharmaceuticals公司于2025年11月发布的2025年第三季财报，其旗舰噬菌体候选药物AP-SA02在复杂性金黄色葡萄球菌感染患者中实现了100%的无復发临床缓解率，充分展现了这些新型生物製药的巨大治疗潜力。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球医院感染治疗市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依药物类型（抗生素、抗真菌药物、抗病毒药物、其他）
  • 依应用领域（血液感染疾病、肺炎、手术部位感染疾病、尿道感染、胃肠道疾病和其他院内感染疾病）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美医院感染治疗市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国别分析
  • 我们
  • 加拿大
  • 墨西哥

第七章：欧洲医院感染治疗市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国别分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区医院感染治疗市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国别分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲医院感染治疗市场展望

• 市场规模及预测
• 市占率及预测
• 中东与非洲：国别分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美洲医院感染治疗市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国别分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 促进因素
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 近期趋势

第十三章：全球医院感染治疗市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的议价能力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Merck & Co., Inc.
• Pfizer Inc.
• Bayer AG
• GlaxoSmithKline Plc.
• Daiichi Sankyo Company, Limited
• AbbVie Inc.
• Abbott Laboratories
• F. Hoffmann-La Roche Ltd
• Allergan Plc.
• AstraZeneca Plc.

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Hospital Infection Therapeutics Market is projected to expand from USD 9.65 Billion in 2025 to USD 13.65 Billion by 2031, progressing at a CAGR of 5.95%. This sector comprises pharmaceutical formulations, including antibiotics, antifungals, and antivirals, utilized to combat nosocomial infections contracted by patients during hospital stays. Market expansion is primarily driven by the growing prevalence of multidrug-resistant pathogens and a global demographic shift towards an aging population, which necessitates extended hospitalizations and complex invasive procedures. Additionally, heightened clinical awareness regarding sepsis and catheter-related complications obliges healthcare facilities to implement advanced antimicrobial protocols, thereby ensuring a sustained demand for effective therapeutic interventions.

Conversely, a substantial hurdle impeding market growth is the lack of economic feasibility in developing novel drugs, resulting in a critical shortage of new treatment options. The exorbitant costs of research, combined with minimal returns on investment for short-course therapies, deter sustained commercial engagement. Data from the International Federation of Pharmaceutical Manufacturers and Associations in 2024 indicated that there was merely one antibiotic candidate in Phase III clinical trials addressing the four bacterial pathogens deemed critical priorities. This scarcity of late-stage candidates highlights the significant financial barriers that currently suppress innovation within the industry.

Market Driver

The rising prevalence of multidrug-resistant pathogens acts as the primary engine driving the Global Hospital Infection Therapeutics Market. As bacteria develop sophisticated resistance mechanisms, standard antibiotic treatments are becoming increasingly ineffective, compelling the adoption of advanced, reserve-line therapeutics. This necessity is intensified by the growing incidence of hospital-acquired infections, particularly within intensive care units where vulnerable patients face elevated risks. In May 2024, the World Health Organization's 'WHO Bacterial Priority Pathogens List 2024' identified 15 families of antibiotic-resistant bacteria as critical priorities for new drug development. Furthermore, the Centers for Disease Control and Prevention reported in July 2024, within its 'Antimicrobial Resistance Threats in the United States, 2021-2022' analysis, that hospital-onset antimicrobial-resistant infections rose by 20% during the COVID-19 pandemic compared to pre-pandemic levels, demonstrating the persistent need for effective medical interventions.

Concurrently, supportive regulatory frameworks and government funding play a vital role in sustaining market momentum by mitigating the high risks associated with antimicrobial drug development. Since the commercial return on short-course antibiotics is often insufficient to attract private equity, public sector investment has become essential for maintaining a robust clinical pipeline. Governments and international organizations are increasingly utilizing push incentives to assist biotech companies through the expensive early stages of research. For instance, the UK Department of Health and Social Care committed £85 million in May 2024, as part of its 'Confronting antimicrobial resistance 2024 to 2029' national action plan, to support global partnerships and research initiatives against antimicrobial resistance. This provision of non-dilutive capital de-risks the development process for pharmaceutical firms, ensuring a consistent flow of novel therapeutic candidates entering the market to address the crisis.

Market Challenge

The most significant obstacle facing the Global Hospital Infection Therapeutics Market is the lack of economic viability in developing novel antimicrobial agents. This structural market failure arises because the high costs associated with research and development are not matched by adequate returns on investment, largely because new antibiotics are typically reserved as last-resort treatments to prevent resistance rather than being sold in high volumes. This adverse economic environment discourages pharmaceutical companies from maintaining their antimicrobial portfolios, leading to a withdrawal of capital and a stagnant pipeline that fails to produce the high-value products necessary for robust market growth.

This disruption in the supply of innovative treatments directly constrains financial expansion by forcing the market to rely on older, lower-cost generics rather than premium novel therapies. A 2024 report by the International Federation of Pharmaceutical Manufacturers and Associations highlighted that, due to these incentive-related challenges, only ten new antibiotics were approved by stringent regulatory authorities between 2017 and 2023, with just two classified as innovative. This minimal output of novel therapeutics severely limits revenue opportunities and inhibits the market's ability to address evolving medical needs.

Market Trends

The integration of AI-driven drug discovery is fundamentally reshaping the Global Hospital Infection Therapeutics Market by accelerating the identification of novel antimicrobial compounds that traditional screening methods often miss. This technological incorporation allows pharmaceutical companies to rapidly analyze vast chemical libraries and predict molecular efficacy against resistant bacterial strains, thereby revitalizing a stagnant clinical pipeline. By utilizing machine learning algorithms, developers can optimize lead candidates for safety and potency at unprecedented speeds, directly addressing the critical shortage of effective treatments for hospital-acquired infections. Highlighting this trend, The Silicon Review reported in March 2025, in an article titled 'Pfizer's $2B AI-Powered Antibiotics to Combat Superbugs', that Pfizer has committed $2 billion to an AI-powered discovery platform specifically designed to automate the identification of next-generation treatments for multidrug-resistant pathogens.

Simultaneously, the market is witnessing the significant emergence of phage therapy as a credible alternative to conventional antibiotics. As bacterial resistance mechanisms compromise standard drug classes, therapeutic focus is shifting toward bacteriophages-viruses that specifically target and neutralize pathogenic bacteria without harming beneficial microbiota or inducing broad-spectrum resistance. This trend represents a paradigm shift from chemical to biological interventions, offering precision treatment options for difficult-to-treat conditions like bacteremia and catheter-associated infections. According to the 'Third Quarter 2025 Results' report from Armata Pharmaceuticals in November 2025, the company's lead phage candidate, AP-SA02, achieved a 100% clinical response rate without relapse in patients with complicated Staphylococcus aureus bacteremia, underscoring the high therapeutic potential of these novel biological agents.

Key Market Players

• Merck & Co., Inc.
• Pfizer Inc.
• Bayer AG
• GlaxoSmithKline Plc.
• Daiichi Sankyo Company, Limited
• AbbVie Inc.
• Abbott Laboratories
• F. Hoffmann-La Roche Ltd
• Allergan Plc.
• AstraZeneca Plc.

Report Scope

In this report, the Global Hospital Infection Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Hospital Infection Therapeutics Market, By Drug Type

• Antibiotics Drugs
• Antifungal Drugs
• Antiviral Drugs
• Others

Hospital Infection Therapeutics Market, By Application

• Bloodstream Infections
• Pneumonia
• Surgical Site Infections
• Urinary Tract Infections
• Gastrointestinal Disorders
• Other Hospital Infections

Hospital Infection Therapeutics Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Hospital Infection Therapeutics Market.

Available Customizations:

Global Hospital Infection Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Hospital Infection Therapeutics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Drug Type (Antibiotics Drugs, Antifungal Drugs, Antiviral Drugs, Others)
  • 5.2.2. By Application (Bloodstream Infections, Pneumonia, Surgical Site Infections, Urinary Tract Infections, Gastrointestinal Disorders, Other Hospital Infections)
  • 5.2.3. By Region
  • 5.2.4. By Company (2025)
• 5.3. Market Map

6. North America Hospital Infection Therapeutics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drug Type
  • 6.2.2. By Application
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Hospital Infection Therapeutics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drug Type
      • 6.3.1.2.2. By Application
  • 6.3.2. Canada Hospital Infection Therapeutics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drug Type
      • 6.3.2.2.2. By Application
  • 6.3.3. Mexico Hospital Infection Therapeutics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drug Type
      • 6.3.3.2.2. By Application

7. Europe Hospital Infection Therapeutics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug Type
  • 7.2.2. By Application
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Hospital Infection Therapeutics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drug Type
      • 7.3.1.2.2. By Application
  • 7.3.2. France Hospital Infection Therapeutics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drug Type
      • 7.3.2.2.2. By Application
  • 7.3.3. United Kingdom Hospital Infection Therapeutics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drug Type
      • 7.3.3.2.2. By Application
  • 7.3.4. Italy Hospital Infection Therapeutics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Drug Type
      • 7.3.4.2.2. By Application
  • 7.3.5. Spain Hospital Infection Therapeutics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Drug Type
      • 7.3.5.2.2. By Application

8. Asia Pacific Hospital Infection Therapeutics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drug Type
  • 8.2.2. By Application
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Hospital Infection Therapeutics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drug Type
      • 8.3.1.2.2. By Application
  • 8.3.2. India Hospital Infection Therapeutics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drug Type
      • 8.3.2.2.2. By Application
  • 8.3.3. Japan Hospital Infection Therapeutics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drug Type
      • 8.3.3.2.2. By Application
  • 8.3.4. South Korea Hospital Infection Therapeutics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Drug Type
      • 8.3.4.2.2. By Application
  • 8.3.5. Australia Hospital Infection Therapeutics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Drug Type
      • 8.3.5.2.2. By Application

9. Middle East & Africa Hospital Infection Therapeutics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drug Type
  • 9.2.2. By Application
  • 9.2.3. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Hospital Infection Therapeutics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drug Type
      • 9.3.1.2.2. By Application
  • 9.3.2. UAE Hospital Infection Therapeutics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drug Type
      • 9.3.2.2.2. By Application
  • 9.3.3. South Africa Hospital Infection Therapeutics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drug Type
      • 9.3.3.2.2. By Application

10. South America Hospital Infection Therapeutics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Drug Type
  • 10.2.2. By Application
  • 10.2.3. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Hospital Infection Therapeutics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Drug Type
      • 10.3.1.2.2. By Application
  • 10.3.2. Colombia Hospital Infection Therapeutics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Drug Type
      • 10.3.2.2.2. By Application
  • 10.3.3. Argentina Hospital Infection Therapeutics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Drug Type
      • 10.3.3.2.2. By Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Hospital Infection Therapeutics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Merck & Co., Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Pfizer Inc.
• 15.3. Bayer AG
• 15.4. GlaxoSmithKline Plc.
• 15.5. Daiichi Sankyo Company, Limited
• 15.6. AbbVie Inc.
• 15.7. Abbott Laboratories
• 15.8. F. Hoffmann-La Roche Ltd
• 15.9. Allergan Plc.
• 15.10. AstraZeneca Plc.

16. Strategic Recommendations

17. About Us & Disclaimer